285 related articles for article (PubMed ID: 32097208)
1. Antidepressant treatment strategy with an early onset of action improves the clinical outcome in patients with major depressive disorder and high anxiety: a multicenter and 6-week follow-up study.
Liao XM; Su YA; Wang Y; Yu X; Si TM
Chin Med J (Engl); 2020 Mar; 133(6):726-728. PubMed ID: 32097208
[No Abstract] [Full Text] [Related]
2. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
[TBL] [Abstract][Full Text] [Related]
3. [Selective serotonin reuptake inhibitors--current knowledge].
Dudek D; Zieba A; Siwek M; Wróbel A
Psychiatr Pol; 2004; 38(3):507-24. PubMed ID: 15199659
[TBL] [Abstract][Full Text] [Related]
4. Psychopharmacological treatment of major depressive disorder in children and adolescents.
Varley CK
JAMA; 2003 Aug; 290(8):1091-3. PubMed ID: 12941683
[No Abstract] [Full Text] [Related]
5. Which SSRIs most effectively treat depression in adolescents?
DeLucia V; Kelsberg G; Safranek S
J Fam Pract; 2016 Sep; 65(9):632-4. PubMed ID: 27672691
[TBL] [Abstract][Full Text] [Related]
6. Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials.
Hayasaka Y; Purgato M; Magni LR; Ogawa Y; Takeshima N; Cipriani A; Barbui C; Leucht S; Furukawa TA
J Affect Disord; 2015 Jul; 180():179-84. PubMed ID: 25911132
[TBL] [Abstract][Full Text] [Related]
7. Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.
Strawn JR; Mills JA; Croarkin PE
J Child Adolesc Psychopharmacol; 2019 May; 29(4):250-255. PubMed ID: 30810350
[No Abstract] [Full Text] [Related]
8. Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: outcome after long-term follow-up.
Peselow ED; Tobia G; Karamians R; Pizano D; IsHak WW
Psychiatry Res; 2015 Feb; 225(3):680-6. PubMed ID: 25496869
[TBL] [Abstract][Full Text] [Related]
9. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
Thase ME; Nierenberg AA; Vrijland P; van Oers HJ; Schutte AJ; Simmons JH
Int Clin Psychopharmacol; 2010 Jul; 25(4):189-98. PubMed ID: 20531012
[TBL] [Abstract][Full Text] [Related]
10. Selective serotonin-reuptake inhibitors in the treatment of panic disorder: a systematic review of placebo-controlled studies.
Mochcovitch MD; Nardi AE
Expert Rev Neurother; 2010 Aug; 10(8):1285-93. PubMed ID: 20662754
[TBL] [Abstract][Full Text] [Related]
11. Sertraline treatment of patients with major depressive disorder who failed initial treatment with paroxetine or fluvoxamine.
Inoue T; Honda M; Kawamura K; Tsuchiya K; Suzuki T; Ito K; Matsubara R; Shinohara K; Ishikane T; Sasaki K; Boku S; Fujisawa D; Ono Y; Koyama T
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):223-7. PubMed ID: 22504727
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs.
Nemeroff CB; Entsuah R; Benattia I; Demitrack M; Sloan DM; Thase ME
Biol Psychiatry; 2008 Feb; 63(4):424-34. PubMed ID: 17888885
[TBL] [Abstract][Full Text] [Related]
13. Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder.
Jakubovski E; Varigonda AL; Freemantle N; Taylor MJ; Bloch MH
Am J Psychiatry; 2016 Feb; 173(2):174-83. PubMed ID: 26552940
[TBL] [Abstract][Full Text] [Related]
14. Neonatal complications after intrauterine exposure to SSRI antidepressants.
Prescrire Int; 2004 Jun; 13(71):103-4. PubMed ID: 15233148
[TBL] [Abstract][Full Text] [Related]
15. The treatment of SSRI-resistant depression in adolescents (TORDIA): in search of the best next step.
Brent DA
Depress Anxiety; 2009; 26(10):871-4. PubMed ID: 19798756
[No Abstract] [Full Text] [Related]
16. Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder.
Papakostas GI; Charles D; Fava M
World J Biol Psychiatry; 2010 Mar; 11(2 Pt 2):300-7. PubMed ID: 20218793
[TBL] [Abstract][Full Text] [Related]
17. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin.
Arias B; Serretti A; Lorenzi C; Gastó C; Catalán R; Fañanás L
J Affect Disord; 2006 Feb; 90(2-3):251-6. PubMed ID: 16356553
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on sertraline in the management of major depressive disorder in elderly patients.
Muijsers RB; Plosker GL; Noble S
CNS Drugs; 2002; 16(11):789-94. PubMed ID: 12383038
[TBL] [Abstract][Full Text] [Related]
19. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
Fava M; Rosenbaum JF; Hoog SL; Tepner RG; Kopp JB; Nilsson ME
J Affect Disord; 2000 Aug; 59(2):119-26. PubMed ID: 10837880
[TBL] [Abstract][Full Text] [Related]
20. Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts.
Schneeweiss S; Patrick AR; Solomon DH; Dormuth CR; Miller M; Mehta J; Lee JC; Wang PS
Pediatrics; 2010 May; 125(5):876-88. PubMed ID: 20385637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
